| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_feddba3d00c27f35e021fe5f4cb2dd5c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2066
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-739 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2017-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89d94470eb633169561a8d226b74678a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a23919cca2addd2532b5d33aa20fe4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd1ee8eaba5bf9adc80435ebb02e3104
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_851f20a1d39b50094c3b9ae7a0c072ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a66c5f1fe107299c344eb646f9b26cbd |
| publicationDate |
2019-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019091290-A1 |
| titleOfInvention |
Macrophage stimulation in cd47 blockade therapy |
| abstract |
Blockade of the CD47/SIRPa pathway depletes cancer cells. This anti-cancer activity is enhanced when macrophage stimulating agents are used in combination with the CD47 blockade drug. This anti-cancer combination therapy is particularly effective when the CD47 blockade drug is SIRPaFc. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11771764-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779631-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11446315-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10906954-B2 |
| priorityDate |
2016-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |